The use of SGLT2 inhibitors in people with diabetes‐related foot disease: A Delphi‐based consensus study
Authors' conclusion
These findings evidence the relative confidence of experienced clinicians in prescribing SGLT2 inhibitors to those with DFD, provided that they do not have a current ulcer and that canagliflozin is not prescribed.
Study context
- Population
- Healthcare practitioners from relevant clinical backgrounds (diabetologists, GPs, nurses, pharmacists); topic: SGLT2i in people with diabetes and diabetes-related foot disease (DFD)19 completed round 2
- Participants
- 21 participants
- Outcome
- Consensus on statements, based on the Average Percent of Majority Opinions
Methodological detailstwo-round online Delphi, convenience sampling, 6-point Likert scale
- Two-round online Delphi
- Convenience sampling
- 6-point Likert scale
Recommendations
As reported in the abstract
Statements reaching consensus
- Statements reaching consensus, of 25 total (13 in round 1, 3 in round 2)
- 16
Original publication
The use of SGLT2 inhibitors in people with diabetes‐related foot disease: A Delphi‐based consensus study. Diabetes Obes Metab. Published 11 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →